Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke
Recruitment status was: Not yet recruiting
In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " The CVA National Action Plan 2013-2014".
Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin plasma level, as for Vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. This link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, CVA.
Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.
|Cerebral Vascular Accident (CVA)||Biological: (for each intervention) Other: Blood test|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:||Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke|
- Determine the minimum level of Copeptin required to determine if the patients present with acute CVA or not. [ Time Frame: Participants will be followed during 90 days ]Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimers in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis
|Study Start Date:||October 2013|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01960478
|Contact: Sébastien HARSCOAT||3 69 55 13 70 ext email@example.com|
|Service des Urgences Médico-Chirugicales Adultes Hôpitaux Universitaires||Not yet recruiting|
|Strasbourg, France, 67098|
|Contact: Sébastien HARSCOAT 03 69 55 13 70 ext 0033 firstname.lastname@example.org|
|Sub-Investigator: Valérie WOLFF|
|Sub-Investigator: Christian MARESCAUX|
|Sub-Investigator: Valérie LAUER|
|Sub-Investigator: Pascal BILBAULT|
|Principal Investigator:||Sébastien HARSCOAT||Hôpitaux Universitaires de Strasbourg|